Analgesics in Dentistry: Non-Opioid and Opioid Principles

Core Review

Acetaminophen (Paracetamol, APAP, Tylenol)

Acetaminophen is the most widely used non-opioid analgesic and a first-line agent for mild to moderate dental pain.

Mechanism of action:

• Works primarily in the CENTRAL NERVOUS SYSTEM (CNS). The exact mechanism is incompletely understood but involves inhibition of central COX enzymes (COX-3 variant or COX-2 in the CNS) and interaction with the endocannabinoid and serotonergic systems. Peripherally, acetaminophen has little to no COX inhibition — this is key to understanding its clinical profile.
• Limited CNS COX inhibition explains its ANALGESIC and ANTIPYRETIC (fever-reducing) effects
• Lack of peripheral COX inhibition explains its LACK of ANTI-INFLAMMATORY effect and LACK of ANTIPLATELET effect

Clinical profile:

• Analgesic: Yes (mild-moderate pain)
• Antipyretic: Yes
• Anti-inflammatory: NO (no peripheral COX inhibition)
• Antiplatelet: NO (no effect on platelet function, no bleeding risk)
• Does NOT cause GI irritation or ulceration (unlike NSAIDs)
• Does NOT affect bleeding time
• Safe in pregnancy (Category B — preferred analgesic during pregnancy)
• Safe in breastfeeding
• No drug interactions with warfarin or other anticoagulants (unlike NSAIDs)

Hepatic toxicity — THE critical adverse effect: Acetaminophen is metabolized primarily by hepatic conjugation (glucuronidation and sulfation) to non-toxic metabolites. A small fraction (~5-10%) is metabolized by CYP2E1 to the toxic intermediate N-acetyl-p-benzoquinoneimine (NAPQI). Under normal conditions, NAPQI is rapidly detoxified by conjugation with glutathione (GSH).

Hepatotoxicity occurs when: (1) Glutathione stores are depleted (overdose, chronic alcoholism, malnutrition, fasting) or (2) CYP2E1 is induced (chronic alcohol use) → NAPQI accumulates → covalent binding to hepatocyte proteins → centrilobular hepatic necrosis → potentially fatal liver failure.

Maximum daily dose: The FDA recommends that the total daily dose of acetaminophen not exceed 4,000 mg for adults (with some authorities recommending 3,000 mg/day as a safer limit). This is a safety ceiling, not a target dose. Verify current recommendations from product labeling.

Dental relevance: Acetaminophen is an excellent choice for dental pain when NSAIDs are contraindicated (GI disease, bleeding disorders, anticoagulant therapy, pregnancy, renal disease) or in combination with an NSAID for multimodal analgesia.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs are among the MOST IMPORTANT and MOST PRESCRIBED analgesics in dentistry. Ibuprofen is the prototype.

Mechanism of action:

• Inhibit cyclooxygenase (COX) enzymes → block conversion of arachidonic acid to prostaglandins (PGE2, PGI2), thromboxane A2 (TXA2), and other prostanoids
• COX-1: Constitutively expressed in most tissues. Maintains gastric mucosal integrity (PGE2, PGI2), regulates renal blood flow, and produces TXA2 for platelet aggregation. Inhibition of COX-1 → GI toxicity, bleeding, renal effects.
• COX-2: Induced at sites of inflammation (by cytokines, growth factors, bacterial LPS). Produces prostaglandins that mediate pain, inflammation, and fever. Inhibition of COX-2 → analgesic, anti-inflammatory, and antipyretic effects.
• Non-selective NSAIDs (ibuprofen, naproxen, ketorolac, indomethacin, diclofenac): Inhibit BOTH COX-1 and COX-2 → analgesic + anti-inflammatory effects BUT also GI and antiplatelet side effects.
• COX-2 selective inhibitors (celecoxib = Celebrex — the only COX-2 selective NSAID currently available in the US): Selectively inhibit COX-2 → analgesic + anti-inflammatory with REDUCED GI toxicity and NO antiplatelet effect. BUT cardiovascular safety concerns (increased risk of MI and stroke with long-term use led to withdrawal of rofecoxib [Vioxx] and valdecoxib [Bextra]).

Clinical profile of non-selective NSAIDs:

• Analgesic: Yes (mild-moderate pain; ibuprofen 400-600 mg is highly effective for dental pain)
• Anti-inflammatory: YES (due to peripheral COX-2 inhibition — the key advantage over acetaminophen)
• Antipyretic: Yes
• Antiplatelet: YES (COX-1 inhibition → reduced TXA2 → impaired platelet aggregation → increased bleeding time). This effect is REVERSIBLE (unlike aspirin) and resolves as the drug is cleared (ibuprofen half-life ~2-4 hours; platelet function recovers within ~24 hours after the last dose).

Adverse effects — the "GI, Renal, Bleeding, Allergic" framework:

1. Gastrointestinal (most common): Dyspepsia, nausea, gastritis, peptic ulcer disease, GI bleeding, perforation. Mechanism: COX-1 inhibition reduces protective prostaglandins (PGE2, PGI2) in gastric mucosa → decreased mucus and bicarbonate secretion, decreased mucosal blood flow, increased acid secretion. Risk increased with: higher dose, longer duration, age >65, history of PUD, concurrent corticosteroid use or anticoagulant use. Mitigation: Take with food; consider proton pump inhibitor (PPI) or misoprostol for high-risk patients; consider COX-2 selective inhibitor.

1. Renal: Reduced renal blood flow (prostaglandins maintain renal perfusion, especially in volume-depleted states; COX inhibition → vasoconstriction of afferent arteriole → reduced GFR). Acute kidney injury in susceptible patients (CHF, cirrhosis, CKD, volume depletion, elderly). Sodium and water retention, edema, hypertension. Contraindicated in significant renal impairment.

1. Bleeding: Reversible inhibition of platelet COX-1 → reduced TXA2 → impaired platelet aggregation → prolonged bleeding time. Clinically significant in patients with bleeding disorders, thrombocytopenia, or on anticoagulant therapy (warfarin, DOACs). Ibuprofen is generally preferred over aspirin when an NSAID is used in patients on aspirin for cardiovascular protection — and should be taken at least 30 minutes after or 8 hours before aspirin to avoid interfering with aspirin's irreversible antiplatelet effect (FDA drug safety communication).

1. Hypersensitivity: Aspirin-exacerbated respiratory disease (AERD, Samter's triad): asthma, nasal polyps, and aspirin/NSAID sensitivity. Cross-reactivity among all non-selective NSAIDs. Patients with AERD generally tolerate acetaminophen and selective COX-2 inhibitors (though cross-reactivity can occur).

1. Cardiovascular: All NSAIDs (except aspirin) may increase the risk of MI and stroke, particularly with long-term use and in patients with established cardiovascular disease. The risk varies by drug and dose. This is primarily a concern for chronic, not short-term, use.

Dental-specific NSAID considerations:

• Ibuprofen and naproxen are available OTC in lower strengths and by prescription in higher strengths
• Ibuprofen is the most studied NSAID for dental pain and has an excellent evidence base for post-operative dental pain
• Ketorolac (Toradol): Potent NSAID, available parenterally (IM, IV). Effective for severe acute pain. Limited to short-term use (≤5 days) due to toxicity
• NSAIDs are anti-inflammatory — a key advantage in dental pain where inflammation (pulpitis, periapical inflammation, post-surgical) is a major component
• Avoid NSAIDs in patients with: active GI bleeding, peptic ulcer disease, severe renal impairment, bleeding disorders, pregnancy (especially 3rd trimester — premature closure of ductus arteriosus), patients on anticoagulants (relative contraindication)

Aspirin (Acetylsalicylic Acid, ASA)

Aspirin is a unique NSAID with irreversible effects.

Mechanism:

• IRREVERSIBLY acetylates COX-1 and COX-2 (covalent modification) → permanent inactivation of the enzyme
• Most other NSAIDs are reversible, competitive inhibitors
• Platelets are anucleate and cannot synthesize new COX-1 → aspirin's antiplatelet effect lasts for the LIFETIME of the platelet (7-10 days)
• Endothelial cells CAN synthesize new COX enzymes → recovery of prostacyclin production

Clinical profile:

• Analgesic, anti-inflammatory, antipyretic (like other NSAIDs)
• Antiplatelet: IRREVERSIBLE (unlike other NSAIDs) → used at low doses (81 mg or 325 mg daily) for cardioprotection (MI prevention, stroke prevention)
• GI toxicity: Significant (COX-1 inhibition + direct mucosal irritant effect — aspirin is acidic)
• Reye syndrome: Aspirin use in children with viral illness (influenza, varicella) is associated with Reye syndrome (acute encephalopathy + hepatic failure). Aspirin is CONTRAINDICATED in children and adolescents with febrile viral illness. Acetaminophen is the preferred antipyretic in children.

Dental relevance:

• Patients on low-dose aspirin for cardioprotection: Aspirin does NOT need to be discontinued for routine dental procedures (including extractions). The risk of thrombotic events (MI, stroke) from discontinuing aspirin far outweighs the risk of prolonged bleeding from dental procedures. Local hemostatic measures (pressure, sutures, hemostatic agents) effectively control bleeding.
• DO NOT use aspirin for dental pain in children or adolescents (Reye syndrome risk)
• Aspirin burn: Placing aspirin directly on the gingiva or tooth for "toothache relief" causes a chemical burn (white, sloughing lesion) — this is a classic NBDHE scenario

Opioid Analgesics: Principles

Opioids are reserved for moderate to severe acute pain when non-opioid analgesics are inadequate. Their use in dentistry is limited and carefully considered given the opioid epidemic.

Mechanism: Agonists at opioid receptors (mu [μ], kappa [κ], delta [δ]) in the CNS and periphery → inhibit ascending pain transmission (spinal cord) and activate descending inhibitory pathways (brainstem). Also produce euphoria, respiratory depression, sedation, and physical dependence (mu receptor).

Common dental opioids:

• Codeine: Prodrug — metabolized by CYP2D6 to morphine (active metabolite). Variable efficacy due to CYP2D6 polymorphisms. Often combined with acetaminophen (Tylenol #3 = codeine 30 mg + acetaminophen 300 mg).
• Hydrocodone: Combined with acetaminophen (Vicodin, Norco = hydrocodone 5/7.5/10 mg + acetaminophen 325 mg).
• Oxycodone: Combined with acetaminophen (Percocet = oxycodone 5/7.5/10 mg + acetaminophen 325 mg).
• Tramadol: Weak mu-opioid agonist + SNRI (serotonin-norepinephrine reuptake inhibitor). Lower abuse potential but still a controlled substance. Lowers seizure threshold. Serotonin syndrome risk with SSRIs/SNRIs.

Adverse effects of opioids:

• Respiratory depression (most serious — cause of death in overdose)
• Constipation (peripheral mu receptors in GI tract — very common)
• Sedation, dizziness, confusion
• Nausea and vomiting (chemoreceptor trigger zone stimulation)
• Pruritus (histamine release)
• Physical dependence and addiction
• Tolerance (requiring escalating doses for the same effect)

Opioid principles for dental practice:

• Opioids are second-line for most dental pain — start with non-opioid analgesics (NSAIDs, acetaminophen)
• When opioids are used, use the lowest effective dose for the shortest duration necessary
• Combine with non-opioid analgesics (multimodal analgesia) to reduce opioid requirements
• Assess for risk factors: personal or family history of substance abuse, psychiatric illness, concurrent use of CNS depressants
• Prescribe limited quantities (acute dental pain typically requires only 2-3 days of opioid coverage)
• Discuss safe storage and disposal of unused medication

Multimodal Analgesia

Combining analgesics with different mechanisms of action provides superior pain relief with LOWER doses of each agent, reducing side effects:

NSAID + Acetaminophen: Synergistic combination. The NSAID provides peripheral anti-inflammatory and analgesic effects; acetaminophen provides central analgesia. This is a highly effective, opioid-sparing strategy for dental pain.

NSAID + Acetaminophen + opioid (if needed): The opioid is added only if NSAID + acetaminophen is insufficient.

Common NBDHE scenario: "Which analgesic regimen provides the most effective pain relief for acute post-operative dental pain with the lowest side effect profile?" → NSAID + acetaminophen combination (multimodal, non-opioid).

Clinical Application

For acute dental pain:

1. First-line: Ibuprofen 400-600 mg OR naproxen (if NSAIDs are not contraindicated) + acetaminophen (combined or staggered)
2. NSAID-contraindicated patients: Acetaminophen alone (or in combination with an opioid for severe pain)
3. If NSAID + acetaminophen insufficient: Add a short course of a low-potency opioid
4. Pregnancy: Acetaminophen preferred; avoid NSAIDs (especially 3rd trimester)
5. Anticoagulated patients: Acetaminophen preferred (NO bleeding risk); avoid NSAIDs
6. GI disease: Acetaminophen preferred; if NSAID needed, add GI protection (PPI) or use COX-2 selective
7. Renal disease: Avoid NSAIDs; acetaminophen preferred with dose adjustment in severe hepatic disease

Common Traps

• Thinking acetaminophen has anti-inflammatory or antiplatelet effects — it doesn't
• Thinking all NSAIDs are equally safe in all patients — contraindications include GI disease, renal impairment, bleeding disorders, pregnancy, and anticoagulant use
• Thinking aspirin must be stopped before dental procedures — low-dose aspirin should be CONTINUED
• Prescribing opioids as first-line for routine dental pain — non-opioid multimodal analgesia is preferred
• Forgetting that aspirin is IRREVERSIBLE while other NSAIDs are REVERSIBLE — explains the 7-10 day antiplatelet effect